Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01G in treatment-naïve stage IV non-small cell lung cancer
2024-515772-12-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab and patritumab deruxtecan in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Merck & Co. Primary endpoints: Objective Response Rate, Number of participants with adverse events and 1 more. Planned start Apr 2025; status: authorised.
02
Drugs
pembrolizumabpatritumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515772-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515772-12-00.